- Home
- NUVB vs IAUX Comparison
NUVB vs IAUX Comparison
Compare NUVB & IAUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVB
- IAUX
- Stock Information
- Founded
- NUVB 2018
- IAUX 2020
- Country
- NUVB United States
- IAUX United States
- Employees
- NUVB N/A
- IAUX N/A
- Industry
- NUVB Biotechnology: Pharmaceutical Preparations
- IAUX
- Sector
- NUVB Health Care
- IAUX
- Exchange
- NUVB Nasdaq
- IAUX Nasdaq
- Market Cap
- NUVB 1.1B
- IAUX 889.5M
- IPO Year
- NUVB N/A
- IAUX N/A
- Fundamental
- Price
- NUVB $5.04
- IAUX $0.92
- Analyst Decision
- NUVB Strong Buy
- IAUX Buy
- Analyst Count
- NUVB 7
- IAUX 1
- Target Price
- NUVB $8.43
- IAUX $1.50
- AVG Volume (30 Days)
- NUVB 8.2M
- IAUX 6.8M
- Earning Date
- NUVB 11-03-2025
- IAUX 11-11-2025
- Dividend Yield
- NUVB N/A
- IAUX N/A
- EPS Growth
- NUVB N/A
- IAUX N/A
- EPS
- NUVB N/A
- IAUX N/A
- Revenue
- NUVB $14,355,000.00
- IAUX $76,622,000.00
- Revenue This Year
- NUVB $291.13
- IAUX $79.79
- Revenue Next Year
- NUVB $332.00
- IAUX $92.04
- P/E Ratio
- NUVB N/A
- IAUX N/A
- Revenue Growth
- NUVB 900.35
- IAUX 40.21
- 52 Week Low
- NUVB $1.54
- IAUX $0.34
- 52 Week High
- NUVB $5.12
- IAUX $1.15
- Technical
- Relative Strength Index (RSI)
- NUVB 76.90
- IAUX 44.88
- Support Level
- NUVB $3.36
- IAUX $0.93
- Resistance Level
- NUVB $3.84
- IAUX $1.03
- Average True Range (ATR)
- NUVB 0.29
- IAUX 0.07
- MACD
- NUVB 0.11
- IAUX -0.02
- Stochastic Oscillator
- NUVB 95.45
- IAUX 5.86
About NUVB Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.